http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Jul+23/26808074.html si-local-file:///var/storage/secattach/20260723/26808074.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Jul+23/26808074.html Thu, 23 Jul 2026 16:07:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Jul+23/26808074.html si-local-file:///var/storage/secattach/20260723/26808074.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Jul+23/26808074.html Thu, 23 Jul 2026 16:07:00 -0400 MGNX O.00725647 http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html <p>MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC), according to a press release issued July 23, 2026.</p> <p>As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion portions of the study. The dose escalation phase evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg every three weeks is now being evaluated in four tumor-specific cohorts: recurrent or metastatic squamous cell carcinoma of the http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html Thu, 23 Jul 2026 16:01:28 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html <p>MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC), according to a press release issued July 23, 2026.</p> <p>As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion portions of the study. The dose escalation phase evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg every three weeks is now being evaluated in four tumor-specific cohorts: recurrent or metastatic squamous cell carcinoma of the http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html Thu, 23 Jul 2026 16:01:28 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html <p>MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC), according to a press release issued July 23, 2026.</p> <p>As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion portions of the study. The dose escalation phase evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg every three weeks is now being evaluated in four tumor-specific cohorts: recurrent or metastatic squamous cell carcinoma of the http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html Thu, 23 Jul 2026 16:01:28 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html <p>MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC), according to a press release issued July 23, 2026.</p> <p>As of July 8, 2026, 74 patients had been enrolled across dose escalation and cohort expansion portions of the study. The dose escalation phase evaluated MGC026 at doses ranging from 1 mg/kg to 9 mg/kg administered every three weeks and was completed in the fourth quarter of 2025. A dose of 7.5 mg/kg every three weeks is now being evaluated in four tumor-specific cohorts: recurrent or metastatic squamous cell carcinoma of the http://www.streetinsider.com/FDA/MacroGenics+reports+Phase+1+progress+for+MGC026+ahead+of+ESMO+2026/26807867.html Thu, 23 Jul 2026 16:01:28 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/FDA/MacroGenics+MGC026+trial+advances+to+stage+2+in+head+and+neck+cancer/26807861.html <p>MacroGenics, Inc. (NASDAQ: MGNX) provided an update on its ongoing Phase 1 study of MGC026, a B7-H3-directed antibody-drug conjugate (ADC), according to a press release dated July 23, 2026.</p> <p>The company said the squamous cell carcinoma of the head and neck (SCCHN) cohort met its pre-specified Stage 1 response threshold under a Simon's two-stage design, and enrollment has advanced to Stage 2, with a planned total of 40 patients in that cohort. Enrollment continues in three additional tumor-specific cohorts: endometrial cancer, melanoma, and soft tissue sarcoma.</p> <p>As of July 8, 2026, 74 patients had been enrolled across the dose escalation and cohort http://www.streetinsider.com/FDA/MacroGenics+MGC026+trial+advances+to+stage+2+in+head+and+neck+cancer/26807861.html Thu, 23 Jul 2026 16:01:15 -0400 MGNX http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026+/26807841.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026+/26807841.html Thu, 23 Jul 2026 16:01:00 -0400 MGNX http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026+/26807841.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026+/26807841.html Thu, 23 Jul 2026 16:01:00 -0400 MGNX http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Press+Releases/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html <ul><li style="margin-top:0in; margin-bottom:12pt;"><i>Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026</i></li><li style="margin-top:0in; margin-bottom:12pt;"><i>Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per Simon’s two-stage design</i></li><li><i>Ongoing enrollment in other tumor-specific cohorts, including endometrial cancer, melanoma and soft tissue sarcoma</i></li></ul> <p><i>ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- </i>MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on the ongoing Phase 1 study evaluating MGC026, a novel B7-H3-directed antibody-drug http://www.streetinsider.com/Globe+Newswire/MacroGenics+Provides+Clinical+Update+on+Ongoing+Phase+1+Study+for+MGC026/26807846.html Thu, 23 Jul 2026 16:01:00 -0400 A.50200911 MGNX O.00725647 O.06886563 http://www.streetinsider.com/New+Coverage/Leerink+Assumes+MacroGenics+%28MGNX%29+at+Outperform/26796281.html <p>Leerink analyst Jeffrey assumes coverage on MacroGenics (NASDAQ: MGNX) with a Outperform rating and a price target of $8.00.</p> <p>For an analyst ratings summary and ratings history on MacroGenics <a href="http://www.streetinsider.com/rating_history.php?q=MGNX">click here</a>. For more ratings news on MacroGenics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=MGNX&amp;type=analyst">click here</a>.</p> <p>Shares of MacroGenics closed at $4.32 yesterday.</p> http://www.streetinsider.com/New+Coverage/Leerink+Assumes+MacroGenics+%28MGNX%29+at+Outperform/26796281.html Tue, 21 Jul 2026 16:49:49 -0400 MGNX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790529.html si-local-file:///var/storage/secattach/20260720/26790529.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790529.html Mon, 20 Jul 2026 17:25:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790529.html si-local-file:///var/storage/secattach/20260720/26790529.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+MILLENNIUM+MANAGEMENT+LLC/26790529.html Mon, 20 Jul 2026 17:25:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Spitznagel+Thomas/26763525.html si-local-file:///var/storage/secattach/20260713/26763525.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Spitznagel+Thomas/26763525.html Mon, 13 Jul 2026 21:26:00 -0400 MGNX O.00725647 http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Spitznagel+Thomas/26763525.html si-local-file:///var/storage/secattach/20260713/26763525.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++MACROGENICS+INC++++++++++++++++++++++++Filed+by%3A+Spitznagel+Thomas/26763525.html Mon, 13 Jul 2026 21:26:00 -0400 MGNX O.00725647 http://www.streetinsider.com/Board+Changes/Karen+Ferrante+to+resign+from+MacroGenics+board+in+September/26747495.html <p>Karen Ferrante, M.D. notified the board of directors of MacroGenics, Inc. (NASDAQ: MGNX) of her decision to resign from the board, effective September 1, 2026.</p><p>According to a statement from the company, Ferrante's resignation is for personal reasons and is not the result of any disagreement with the company or any matter relating to its operations, policies, or practices.</p> http://www.streetinsider.com/Board+Changes/Karen+Ferrante+to+resign+from+MacroGenics+board+in+September/26747495.html Wed, 08 Jul 2026 16:02:48 -0400 MGNX http://www.streetinsider.com/Corporate+News/Karen+Ferrante+to+resign+from+MacroGenics+board+in+September/26747495.html <p>Karen Ferrante, M.D. notified the board of directors of MacroGenics, Inc. (NASDAQ: MGNX) of her decision to resign from the board, effective September 1, 2026.</p><p>According to a statement from the company, Ferrante's resignation is for personal reasons and is not the result of any disagreement with the company or any matter relating to its operations, policies, or practices.</p> http://www.streetinsider.com/Corporate+News/Karen+Ferrante+to+resign+from+MacroGenics+board+in+September/26747495.html Wed, 08 Jul 2026 16:02:48 -0400 MGNX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Jul+01/26747466.html si-local-file:///var/storage/secattach/20260708/26747466.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MACROGENICS+INC+++++++++++For%3A+Jul+01/26747466.html Wed, 08 Jul 2026 16:01:00 -0400 MGNX O.00725647